8 research outputs found
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation of the molecular mechanisms of action of p53 reactivating molecules with alternative functional principle is of the utmost importance. Here, we report a discovery of a novel allosteric mechanism of p53 reactivation through targeting the p53 N-terminus which promotes inhibition of both p53/MDM2 (murine double minute 2) and p53/MDM4 interactions. Using biochemical assays and molecular docking, we identified the binding site of two p53 reactivating molecules, RITA (reactivation of p53 and induction of tumor cell apoptosis) and protoporphyrin IX (PpIX). Ion mobility-mass spectrometry revealed that the binding of RITA to serine 33 and serine 37 is responsible for inducing the allosteric shift in p53, which shields the MDM2 binding residues of p53 and prevents its interactions with MDM2 and MDM4. Our results point to an alternative mechanism of blocking p53 interaction with MDM2 and MDM4 and may pave the way for the development of novel allosteric inhibitors of p53/MDM2 and p53/MDM4 interactions
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation of the molecular mechanisms of action of p53 reactivating molecules with alternative functional principle is of the utmost importance. Here, we report a discovery of a novel allosteric mechanism of p53 reactivation through targeting the p53 N-terminus which promotes inhibition of both p53/MDM2 (murine double minute 2) and p53/MDM4 interactions. Using biochemical assays and molecular docking, we identified the binding site of two p53 reactivating molecules, RITA (reactivation of p53 and induction of tumor cell apoptosis) and protoporphyrin IX (PpIX). Ion mobility-mass spectrometry revealed that the binding of RITA to serine 33 and serine 37 is responsible for inducing the allosteric shift in p53, which shields the MDM2 binding residues of p53 and prevents its interactions with MDM2 and MDM4. Our results point to an alternative mechanism of blocking p53 interaction with MDM2 and MDM4 and may pave the way for the development of novel allosteric inhibitors of p53/MDM2 and p53/MDM4 interactions
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
Human DNA polymerase theta (Polθ), which is essential
for
microhomology-mediated DNA double strand break repair, has been proposed
as an attractive target for the treatment of BRCA deficient and other
DNA repair pathway defective cancers. As previously reported, we recently
identified the first selective small molecule Polθ in vitro
probe, 22 (ART558), which recapitulates the phenotype
of Polθ loss, and in vivo probe, 43 (ART812), which
is efficacious in a model of PARP inhibitor resistant TNBC in vivo.
Here we describe the discovery, biochemical and biophysical characterization
of these probes including small molecule ligand co-crystal structures
with Polθ. The crystallographic data provides a basis for understanding
the unique mechanism of inhibition of these compounds which is dependent
on stabilization of a “closed” enzyme conformation.
Additionally, the structural biology platform provided a basis for
rational optimization based primarily on reduced ligand conformational
flexibility
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
Human DNA polymerase theta (Polθ), which is essential
for
microhomology-mediated DNA double strand break repair, has been proposed
as an attractive target for the treatment of BRCA deficient and other
DNA repair pathway defective cancers. As previously reported, we recently
identified the first selective small molecule Polθ in vitro
probe, 22 (ART558), which recapitulates the phenotype
of Polθ loss, and in vivo probe, 43 (ART812), which
is efficacious in a model of PARP inhibitor resistant TNBC in vivo.
Here we describe the discovery, biochemical and biophysical characterization
of these probes including small molecule ligand co-crystal structures
with Polθ. The crystallographic data provides a basis for understanding
the unique mechanism of inhibition of these compounds which is dependent
on stabilization of a “closed” enzyme conformation.
Additionally, the structural biology platform provided a basis for
rational optimization based primarily on reduced ligand conformational
flexibility
The structure of p53 tumour suppressor protein reveals the basis for its funcitonal plasticity
p53 major tumour suppressor protein has presented a challenge for structural biology for two decades. The intact and complete p53 molecule has eluded previous attempts to obtain its structure, largely due to the intrinsic flexibility of the protein. Using ATP-stabilised p53, we have employed cryoelectron microscopy and single particle analysis to solve the first three-dimensional structure of the full-length p53 tetramer (resolution 13.7 Å). The p53 molecule is a D2 tetramer, resembling a hollow skewed cube with node-like vertices of two sizes. Four larger nodes accommodate central core domains, as was demonstrated by fitting of its X-ray structure. The p53 monomers are connected via their juxtaposed N- and C-termini within smaller N/C nodes to form dimers. The dimers form tetramers through the contacts between core nodes and N/C nodes. This structure revolutionises existing concepts of p53's molecular organisation and resolves conflicting data relating to its biochemical properties. This architecture of p53 in toto suggests novel mechanisms for structural plasticity, which enables the protein to bind variably spaced DNA target sequences, essential for p53 transactivation and tumour suppressor functions